Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$3.07
-0.6%
$3.26
$2.80
▼
$8.40
$784.28M0.794.88 million shs3.80 million shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$25.43
+0.4%
$23.08
$21.43
▼
$50.79
$775.33M0.75644,982 shs494,891 shs
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$17.03
$17.03
$13.08
▼
$21.03
$884.18M0.25680,323 shsN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$3.81
-4.5%
$4.47
$3.57
▼
$9.94
$238.85M0.741.32 million shs839,226 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ardelyx, Inc. stock logo
ARDX
Ardelyx
0.00%+7.29%0.00%-23.89%-47.27%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
0.00%+4.58%+9.18%-9.80%-44.93%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
0.00%0.00%0.00%+0.65%-2.07%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.00%+4.45%-0.99%-24.14%-8.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$3.07
-0.6%
$3.26
$2.80
▼
$8.40
$784.28M0.794.88 million shs3.80 million shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$25.43
+0.4%
$23.08
$21.43
▼
$50.79
$775.33M0.75644,982 shs494,891 shs
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$17.03
$17.03
$13.08
▼
$21.03
$884.18M0.25680,323 shsN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$3.81
-4.5%
$4.47
$3.57
▼
$9.94
$238.85M0.741.32 million shs839,226 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ardelyx, Inc. stock logo
ARDX
Ardelyx
0.00%+7.29%0.00%-23.89%-47.27%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
0.00%+4.58%+9.18%-9.80%-44.93%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
0.00%0.00%0.00%+0.65%-2.07%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.00%+4.45%-0.99%-24.14%-8.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ardelyx, Inc. stock logo
ARDX
Ardelyx
2.92
Moderate Buy$13.60343.00% Upside
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.90
Moderate Buy$44.0073.02% Upside
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.00
Hold$19.0011.57% Upside
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
2.56
Moderate Buy$13.50254.33% Upside

Current Analyst Ratings Breakdown

Latest VNDA, TBPH, ARDX, and COLL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Lower Price TargetOverweight$48.00 ➝ $41.00
11/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
UpgradeSell (D+) ➝ Hold (C-)
11/9/2026
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Lower Price TargetBuy$14.00 ➝ $11.00
11/6/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Reiterated RatingBuy$35.00
11/6/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Lower Price TargetNeutral$43.00 ➝ $28.00
11/5/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Lower Price TargetBuy$46.00 ➝ $44.00
11/4/2026
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Initiated CoverageStrong-Buy
11/4/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
UpgradeStrong Sell ➝ Hold
11/2/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Reiterated RatingBuy
10/16/2026
Ardelyx, Inc. stock logo
ARDX
Ardelyx
UpgradeStrong Sell ➝ Hold
10/15/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Reiterated RatingSell (D-)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$407.32M1.89N/AN/A$0.65 per share4.72
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$780.57M1.01$15.51 per share1.64$9.54 per share2.67
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$104.31M8.48N/AN/A$5.86 per share2.91
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$216.10M1.07N/AN/A$3.31 per share1.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$61.60M-$0.22N/A16.16N/A-11.85%-35.30%-10.23%N/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$62.87M$1.003.764.320.784.68%85.14%13.80%N/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$105.89M$1.0116.8621.02N/A51.58%-0.77%-0.46%N/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$220.47M-$4.62N/AN/AN/A-119.87%-62.70%-37.53%N/A

Latest VNDA, TBPH, ARDX, and COLL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.86$1.96+$0.10$0.60$216.03 million$216.34 million
10/28/2026Q3 2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.6820-$0.37+$0.3120-$0.37$69.20 million$69.82 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1.54
3.45
3.26
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.44
1.01
0.87
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/A
13.54
13.54
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.01
1.54
1.53

Institutional Ownership

CompanyInstitutional Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
99.10%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%

Insider Ownership

CompanyInsider Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
5.30%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
1.85%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
7.65%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
489251.37 million238.05 millionOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
42331.08 million30.50 millionOptionable
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
11051.92 million47.95 millionOptionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
53360.47 million54.00 millionOptionable

Recent News About These Companies

Vanda Pharmaceuticals Earnings Call Signals Growth Amid Risks
What is HC Wainwright's Forecast for VNDA FY2026 Earnings?
Vanda (VNDA) Q3 2026 Earnings Call Transcript
Vanda Pharmaceuticals Q3 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$3.07 -0.02 (-0.65%)
Closing price 04:00 PM Eastern
Extended Trading
$3.06 0.00 (-0.16%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$25.43 +0.11 (+0.43%)
Closing price 04:00 PM Eastern
Extended Trading
$25.44 +0.02 (+0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Theravance Biopharma stock logo

Theravance Biopharma NASDAQ:TBPH

$17.03 0.00 (0.00%)
As of 11/6/2026

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$3.81 -0.18 (-4.51%)
Closing price 04:00 PM Eastern
Extended Trading
$3.81 0.00 (-0.08%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.